OMC Financial Services LTD Acquires Shares of 13,910 Johnson & Johnson (NYSE:JNJ)

OMC Financial Services LTD bought a new position in Johnson & Johnson (NYSE:JNJ) in the 1st quarter, Holdings Channel.com reports. The institutional investor bought 13,910 shares of the company’s stock, valued at approximately $2,200,000. Johnson & Johnson accounts for approximately 1.1% of OMC Financial Services LTD’s portfolio, making the stock its 21st largest holding.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Christopher J. Hasenberg Inc bought a new position in shares of Johnson & Johnson in the first quarter valued at approximately $31,000. Keener Financial Planning LLC bought a new stake in Johnson & Johnson during the fourth quarter worth about $40,000. WFA Asset Management Corp raised its holdings in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the 4th quarter worth approximately $44,000. Finally, Disciplined Equity Management Inc. purchased a new stake in Johnson & Johnson in the fourth quarter worth approximately $45,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 2.1 %

JNJ stock traded up $3.38 on Friday, reaching $164.14. 11,280,357 shares of the company traded hands, compared to its average volume of 7,234,699. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The firm has a fifty day simple moving average of $149.73 and a 200-day simple moving average of $153.19. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The company has a market cap of $395.12 billion, a P/E ratio of 10.23, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.80 EPS. Research analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Analysts Set New Price Targets

JNJ has been the topic of several research reports. Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the stock from $169.00 to $170.00 in a report on Thursday, April 18th. TD Cowen dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Finally, Morgan Stanley increased their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.